Obstet Gynecol Sci.  2013 Jul;56(4):273-276.

Pulmonary embolism and deep vein thrombosis related to oral contraceptive use

• Kim JY
• Kim YS

Abstract

Pulmonary embolism (PE) and deep vein thrombosis (DVT) is a serious medical problem causing considerable morbidity and mortality. Risk factors of thrombosis are surgery, trauma, pregnancy, tumor, oral contraceptive as well as genetic risk factors though genetic risk factors were found in about 5% to 10% of cases. Yasmin, a combined oral contraceptive containing ethinylestradiol 30 microg and drospirenon 3 mg was launched in the United Kingdom in 2002. We had experienced a patient, 24-year-old young woman with left inguinal pain on ambulation, and edema of left leg four months after taking Yasmin. We performed chest pulmonary angiography computed tomography (CT) and lower extremity venogram CT. She was diagnosed to PE in both lower lobes and DVT below the level of left external iliac vein, and treated by low molecular weight heparin and warfarin. We report this case with brief review of literatures.

Keyword

Deep vein thrombosis; Oral contraceptive; Pulmonary embolism

MeSH Terms

Androstenes
Angiography
Edema
Ethinyl Estradiol
Female
Great Britain
Heparin, Low-Molecular-Weight
Humans
Iliac Vein
Leg
Lower Extremity
Pregnancy
Pulmonary Embolism
Risk Factors
Thorax
Thrombosis
Venous Thrombosis
Walking
Warfarin
Androstenes
Ethinyl Estradiol
Heparin, Low-Molecular-Weight
Warfarin

Figure

• 

  Fig. 1 Chest pulmonary angiography computed tomography (contrast enhanced) showed positron emission tomography in both lower lobes basal pulmonary arteries and 32-mm sized extent consolidation (arrow) in right lower lobe posterior segment considering pulmonary infarction.

• 

  Fig. 2 Lower extremity venogram computed tomography (contrast enhanced) showing diffuse deep vein thrombosis (arrow) below the level of left external iliac vein.

Reference

1. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001. 344:1527–1535.

2. Pearce HM, Layton D, Wilton LV, Shakir SA. Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin. Br J Clin Pharmacol. 2005. 60:98–102.

3. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 2001. 323:131–134.

4. Chroustova D, Kubinyi J, Jansa P, Veprekova L, Trnka J. V/P scan in diagnosis and follow-up of pulmonary embolism in 15-25-year-old females in relation to hormonal contraception use. Nucl Med Rev Cent East Eur. 2011. 14:63–67.

5. Goldhaber SZ, Morrison RB. Cardiology patient pages. Pulmonary embolism and deep vein thrombosis. Circulation. 2002. 106:1436–1438.

6. Hirsch DR, Mikkola KM, Marks PW, Fox EA, Dorfman DM, Ewenstein BM, et al. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J. 1996. 131:1145–1148.

7. Rosen SB, Sturk A. Activated protein C resistance--a major risk factor for thrombosis. Eur J Clin Chem Clin Biochem. 1997. 35:501–516.

8. Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ. 2011. 183:E1319–E1325.

9. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. 2011. 342:d2151.

10. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ. 2011. 342:d2139.

11. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009. 339:b2890.

12. Committee on Gynecologic Practice. ACOG Committee Opinion Number 540: risk of venous thromboembolism among users of drospirenone-containing oral contraceptive pills. Obstet Gynecol. 2012. 120:1239–1242.